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BACKGROUND
Different clinical presentations of disease caused by Mycoplasma
bovis predominate in European countries with significant economic
and welfare impacts. M. bovis disease control relies on good
husbandry and an early and reliable diagnosis. However, a lack of
standardisation of approaches and diagnostic methods applied makes
comparison of disease prevalence between countries difficult.
AIMS
• With assistance from CoVetLab.org a consortium of six European
national veterinary institutes was established to develop a network
of scientists and share tools and expertise on Mycoplasma bovis.
• Objectives included hosting workshops and developing ring trials,
including collating panels of DNA and serum samples, to evaluate
available serological and PCR-based diagnostic tests.
CoVetLab: working together to strengthen European collaboration
on Mycoplasma bovis and compare available diagnostic tools
CONCLUSIONS 
• This CoVetLab project has enabled scientists from veterinary 
institutes in Europe undertaking M. bovis diagnostics to 
collaborate on mutually agreed priorities. 
• A joint CoVetLab -Nordic Workshop extended opportunities to 
widen our network of scientists and present preliminary data.
• The comparison of PCR tests has provided reassurance regarding 
the quality of diagnosis, despite the different target genes and 
assays used in our laboratories.
• Although only commercial ELISA kits were included, differences 
in the sensitivity and specificity were obtained. 
• Highlights the importance of inter-laboratory studies to assess 
performance of current and newly available tests.
• References: Wisselink et al. "A European interlaboratory trial to evaluate the performance 
of different PCR methods for Mycoplasma bovis diagnosis" accepted BMC Veterinary 
Research.
Andersson et al. (in preparation). 
• Analytical specificity, sensitivity and comparability of seven different 
PCR methods used to detect M. bovis were assessed. 
• All methods were in use by at least one of the participants.
• Five different DNA extraction methods, seven PCRs targeting four 
different genes and six different real-time PCR platforms. 
• One commercial kit, all other PCR assays were in-house tests. 
M. bovis ELISA RING TRIAL
• Two commercial ELISA systems (ID screen ELISA (Idvet, Grabels, 
France) and BIO K302 ELISA (Bio-X Diagnostics, Rochefort, 
Belgium)) were assessed by inter-laboratory comparison. 
• The sample panel (n=180) comprised sera from cattle from five 
countries with high and low M. bovis prevalence. 
• Standardised set of samples designed to reflect the range of 
samples encountered in all partner countries
• Sera were distributed to the six laboratories and tested as 
recommended by the suppliers of the test kits.
• Inter-laboratory variation associated with transferability of in-
house assays precludes meaningful comparisons and so were not 
included in the analyses.
• Immunoblot enabled statistical evaluation by latent class analysis. 
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• The ID Screen ELISA showed highest agreement with Western blot 
analysis and performed with higher precision and accuracy than 
the Bio K302 ELISA (Fig 2). 
• The diagnostic sensitivities of the ID Screen® Mycoplasma bovis
and the Bio K302 ELISA were 95.6 % and 48.8 % respectively, with 
specificities of 99.3 % and 88.3 %, respectively.
M. bovis PCR RING TRIAL
WORKSHOPS
A B
A. At Ruokavirasto in Kuopio to develop PCR and ELISA ring trials.
B. Joint CoVetLab - Nordic Workshop on M. bovis in March 2018 at 
DTU, Lyngby was attended by 45 participants from the veterinary 
and scientific community from 10 countries.
• Analytical specificity of the PCR methods was comparable, 
although only PCR-DGGE identified other bovine mycoplasmas.
• Limits of detection varied from 10 to 103 CFU/ml to 103 and 106
CFU/ml for real-time and end-point assays, respectively. 
• Ct values varied with naturally infected samples, both between 
laboratories and tests, without affecting interpretation (Fig 1).  
Fig 2. Assessing sensitivity and specificity of the ELISA and immunoblot tests
Fig 1. 
